产品说明书
Candesartan
 |
同义名 : | CV 11974;Candesartan M1;Candesartan, CV11974, CV-1197, CV 11974, Trade names: Blopress, Atacand, Amias, and Ratacand |
| CAS号 : | 139481-59-7 | |
| 货号 : | A148921 | |
| 分子式 : | C24H20N6O3 | |
| 纯度 : | 95% | |
| 分子量 : | 440.454 | |
| MDL号 : | MFCD00864463 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(238.39 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
2% DMSO+40% PEG 300+2% Tween 80+water 10 mg/mL |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM. In vivo research shows that conducted on 5XFAD mice, 2-months intranasal treatment with candesartan resulted in reduced Aβ deposits and microglial accumulation in the hippocampus but not in the cortex. In vitro, reduced IL-1β levels in 4-hour LPS-stimulated cortical microglia (100 ng/mL) following 2-hour pretreatment with candesartan (10 μM)[3]. It is a prolonged angiogenic effect, associated with enhanced VEGF-A and VEGF-B expression in vitro and in vivo, in response to a single dose of candesartan treatment[4]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00863980 | Acute Myocardial Infarction ... 展开 >> Angina Pectoris Myocardial Ischemia Acute Coronary Syndrome Hypertension 收起 << | Not Applicable | Terminated(Principle investiga... 展开 >>tor resigned in 2013) 收起 << | - | Japan ... 展开 >> Shakaihoken Kobe Central Hospital Kobe, Japan, 651-1145 Akashi Municipal Hospital Kobe, Japan, 673-8501 Kouseikai Takeda Hospital Kyoto, Japan, 600-8558 Aijyukai Dohjin Hospital Kyoto, Japan, 602-0917 Kyoto Second Red Cross Hospital Kyoto, Japan, 602-8026 Kyoto Prefectural University of Medicine Kyoto, Japan, 602-8566 Social Insurance Kyoto Hospital Kyoto, Japan, 603-8151 Kyoto Kojyo Hokenkai Kyoto, Japan, 604-8472 Kyoto City Hospital Kyoto, Japan, 604-8845 Kyoto First Red Cross Hospital Kyoto, Japan, 605-0981 Aiseikai Yamashina Hospital Kyoto, Japan, 607-8086 Tanabe Central Hospital Kyoto, Japan, 610-0334 Rakusai Simizu Hospital Kyoto, Japan, 610-1106 Uji Hospital Kyoto, Japan, 611-0011 Kyoto Yawata Hospital Kyoto, Japan, 614-8114 Seizinkai Simizu Hospital Kyoto, Japan, 615-8237 Saiseikai Kyoto Hospital Kyoto, Japan, 617-0814 Public Yamasiro Hospital Kyoto, Japan, 619-0214 Gakkentoshi Hospital Kyoto, Japan, 619-0238 Fukuchiyama City Hospital Kyoto, Japan, 620-8505 Ayabe City Hospital Kyoto, Japan, 623-0011 Maizuru Red Cross Hospital Kyoto, Japan, 624-0906 National Hospital Organization Maizuru Medical Center Kyoto, Japan, 625-8502 Maizuru Kyosai Hospital Kyoto, Japan, 625-8585 Public Nantan Hospital Kyoto, Japan, 629-0197 Kyoto Prefectural Yosanoumi Hospital Kyoto, Japan, 629-2261 Kumihama Hospital Kyoto, Japan, 629-3403 Sakurakai Takahashi Hospital Kyoto, Japan, 654-0026 Yuuseikai Midorigaoka Hospital Osaka, Japan, 569-1121 Matsushita Memorial Hospital Osaka, Japan, 570-8540 Saiseikai Shiga Hospital Shiga, Japan, 520-3046 Omihachiman Community Medical Center Shiga, Japan, 523-0892 收起 << |
| NCT00130975 | Atrial Fibrillation | Phase 3 | Completed | - | Norway ... 展开 >> Ulleval University Hospital Oslo, Norway, 0407 Asker & Baerum Hospital Rud, Norway, 1309 收起 << |
| NCT00150631 | Hypertension | Phase 3 | Unknown | December 2014 | Denmark ... 展开 >> Karin Skov Aarhus, Denmark, 8000 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.27mL 0.45mL 0.23mL |
11.35mL 2.27mL 1.14mL |
22.70mL 4.54mL 2.27mL |
| 参考文献 |
|---|